Introduction and Objective: Type 2 diabetes (T2D) and obesity are independently associated with increased risk of cardiovascular disease (CVD) and kidney outcomes. This study aimed to explore the impact of body mass index (BMI) at T2D diagnosis on CVD and kidney outcomes, which is less understood.Methods: Data from people diagnosed with T2D from January 2010 to March 2021 were extracted from Clinical Practice Research Datalink Aurum and linked Hospital Episode Statistics datasets in England. Ten-year incidence of CVD and kidney outcomes were estimated in males and females by BMI subgroup using parametric survival models.Results: Data from 161,109 people (60.6% male) with T2D were included. Ten-year incidence of CVD [and kidney outcomes] in males with BMI 35-40 and 40-50 kg/m2 were 43.1% and 47.9% [23.6% and 26.6%] respectively (vs 38.7% [20.6%] in BMI 18-30 kg/m2; p<0.05; Fig 1). Females with BMI 40-50 kg/m2 had higher 10-year incidence of CVD [and kidney outcomes] of 33.6% [27.8%] (vs 28.2% [22.5%] in BMI 18-30 kg/m2; p<0.05).Conclusion: Males with BMI > 35 kg/m2 and females > 40 kg/m2 at T2D diagnosis have higher risk and earlier manifestation of CVD and kidney outcomes. Timely screening and appropriate weight management in these populations could support management of this increased risk and potentially reduce healthcare burden associated with CVD and kidney complications.
A.B. Jain: Advisory Panel; Abbott. Speaker’s Bureau; Abbott. Research Support; Abbott. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker’s Bureau; Novo Nordisk. Research Support; AstraZeneca, Amgen Inc. Speaker’s Bureau; Amgen Inc. Advisory Panel; Amgen Inc. Research Support; Sanofi. Advisory Panel; Bausch Health. Speaker’s Bureau; Bausch Health. Advisory Panel; Bayer Pharmaceuticals, Inc. Speaker’s Bureau; Bayer Pharmaceuticals, Inc, Boehringer-Ingelheim. Advisory Panel; Dexcom, Inc. Speaker’s Bureau; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Speaker’s Bureau; Eli Lilly and Company. Advisory Panel; HLS Therapeutics. Speaker’s Bureau; HLS Therapeutics, Medtronic. Advisory Panel; Insulet Corporation. Speaker’s Bureau; Insulet Corporation. Advisory Panel; Sandoz. P.N. Kristensen: Stock/Shareholder; Novo Nordisk. Employee; Novo Nordisk. R. Wasehuus: Employee; Novo Nordisk A/S. J. Hollinghurst: Consultant; Novo Nordisk A/S, AbbVie Inc, AstraZeneca, GlaxoSmithKline plc, Pfizer Inc, Shionogi & Co., Ltd, Galapagos, Rocket Pharma, ViiV Healthcare. E. Noertoft: Employee; Novo Nordisk A/S.
Source link
Leave a Reply